Aeva Technologies vs. Cognex: Which Computer Vision Stock Is a Better Buy in 2026?

Aeva Technologies posted FY2025 revenue of $18.1 million, up 99.4% year over year, but still reported a net loss of about $145.4 million and negative free cash flow of nearly $119.7 million. Cognex generated $994.4 million of FY2025 revenue, produced $114.4 million of net income, and delivered $236.8 million of free cash flow, highlighting a much stronger balance sheet and profitability profile. The article favors Cognex over Aeva for 2026, citing Cognex’s lower leverage, diversified end markets, and better resilience despite competition and macro risks.

Analysis

The cleaner read is that this is less a debate about sensing technology and more about capital structure under uneven adoption. The market is rewarding CGNX because it can self-fund product cycles and absorb a slowdown without diluting holders, while AEVA is still in the phase where every incremental dollar of revenue carries a large fixed-cost burden; that means any delay in design wins or OEM SOPs likely shows up first as financing pressure, not just slower growth. In other words, AEVA’s equity is effectively a long-dated option on manufacturing execution, while CGNX is a compounding cash-flow franchise.

Second-order, CGNX may actually benefit from the same automation narrative that investors use to justify AEVA, because industrial customers can deploy vision systems sooner and with lower integration risk than next-gen lidar. If OEM and logistics budgets tighten over the next 1-2 quarters, buyers are more likely to choose incremental automation upgrades over platform bets, which should preserve CGNX’s demand mix and put pressure on speculative adjacent names. The real competitive risk for AEVA is not just Tesla or in-house sensing; it is that customers defer full-stack autonomy and spend on cheaper perception layers first.

The key catalyst for AEVA is a credible step-up in revenue quality, not revenue quantity: multiple quarters of reduced customer concentration, improving gross margin, and evidence of repeatable volume shipments. Absent that, the balance sheet and negative free cash flow create a financing overhang that can cap the stock for months even if sentiment turns favorable. For CGNX, the main risk is not business model failure but valuation compression if macro weakens; still, that is a slower-moving risk given its cash generation and balance-sheet flexibility.

Key Decisions for Investors

• Long CGNX / short AEVAW as a 6-12 month pair trade: own the profitable automation compounder against the pre-profitability option value; target outperformance if OEM capex budgets stay selective and AEVA needs external capital.
• Use CGNX pullbacks after macro-driven selloffs to add exposure; risk/reward is favorable over 3-6 months because downside is cushioned by cash flow and balance-sheet strength, while upside can re-rate on continued earnings beats.
• Avoid initiating new long AEVAW ahead of a financing or follow-on-risk window; if you want exposure, structure it as a small call-spread over 9-18 months so downside is capped and the position only pays if commercial traction accelerates materially.
• If AEVAW rallies on design-win headlines, fade strength unless you also see sequential revenue acceleration and lower customer concentration over the next 2-3 quarters; otherwise the move is likely narrative-driven rather than fundamentals-driven.
• Consider CGNX calls or call spreads into the next earnings cycle if the market over-discounts industrial demand; the company’s low leverage and strong FCF create asymmetric upside on any modest beat/re-raise.